STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7
Clinical trials for STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7 trials appear
Sign up with your email to follow new studies for STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets genetic weakness in advanced bladder cancer
Disease control OngoingThis study tested a drug called sapanisertib in 17 people with advanced bladder cancer that has a specific change in the TSC1 or TSC2 gene. The drug works by blocking a protein that helps cancer cells grow. The goal was to see if the drug could shrink tumors and how well people t…
Matched conditions: STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 01:49 UTC
-
Immunotherapy combo shows promise for tough bladder cancers
Disease control OngoingThis early-phase study tested two immunotherapy drugs, durvalumab and tremelimumab, given before surgery to patients with aggressive bladder cancer who cannot receive standard chemotherapy. The main goal was to check safety and side effects. Researchers also looked at how the dru…
Matched conditions: STAGE III BLADDER UROTHELIAL CARCINOMA AJCC V6 AND V7
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 01:37 UTC